Quantifying the Impact of Insurance Coverage for IVF on Maternal and Infant Health
量化 IVF 保险范围对母婴健康的影响
基本信息
- 批准号:10662388
- 负责人:
- 金额:$ 46.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAffectAgeBirthBirth RateCategoriesChildbirthDataDiseaseEmbryoEventExclusionExpenditureFertilization in VitroFinancial HardshipGoalsHealthHealth InsuranceHealth PolicyHealthcare SystemsHemorrhageIncentivesIncidenceIncomeInfantInfant HealthInfertilityInsuranceInsurance CoverageKnowledgeLeftLength of StayMaternal AgeMaternal HealthMedicalMothersMultiple Birth OffspringNeonatal Intensive Care UnitsOutcomePatient TransferPatientsPerinatalPoliciesPolicy MakerPopulationPremature BirthPublic HealthReportingResearchResearch PersonnelRiskSamplingSerious Adverse EventSurveysTestingTimeTriplet Multiple BirthTwin Multiple BirthUninsured Medical ExpenseUnited StatesWomanWomen&aposs HealthWorkage groupagedcosteffective therapyevidence baseexperiencefinancial incentivehealth care service utilizationhigh riskhospital readmissionimprovedinfant morbidityinfant morbidity/mortalityinfertility treatmentinnovationmaternal morbiditymultidisciplinarynovel strategiespsychologicreproductivestemyoung woman
项目摘要
PROJECT SUMMARY
Much remains unknown about how the presence or absence of insurance coverage for in-vitro fertilization
(IVF) affects the health outcomes of women and infants, health care utilization, and IVF use among less
affluent and younger women. The investigators’ long-term goal is to generate compelling new evidence that
can improve the health of women and infants. The objective of this application is to quantify the impact of
insurance coverage for IVF on women with infertility and their infants. The central hypothesis is that insurance
coverage for IVF is associated with improved IVF-related health outcomes for women and infants; reduced net
health care utilization and total medical expenditures during the first year after birth; and increased IVF use
among less affluent and younger women by mitigating a key financial barrier that influences how women use
IVF. The rationale for this project stems from the fact that few health insurance plans cover IVF, which leads to
two main issues. First, many women forgo or delay using IVF due to cost, and IVF is more successful and has
fewer complications when performed at younger ages. Second, when left to pay $15,000 out-of-pocket for an
IVF cycle, women have a financial incentive to increase the likelihood of a birth by transferring multiple
embryos during that IVF cycle. There is no additional cost to patients for transferring multiple embryos, but
doing so greatly increases the chance of having high-risk twin, triplet, or other higher-order multiple births.
Surveys of diverse women with infertility have shown that they are willing to transfer fewer embryos per IVF
cycle if IVF is covered by insurance. The central hypothesis will be tested by pursuing three Specific Aims: 1)
Evaluate the impact of insurance coverage for IVF on health outcomes for women and infants; 2)
Determine the impact of insurance coverage for IVF on health care utilization; and 3) Examine the
impact of insurance coverage for IVF on IVF use in different income and age groups. All three Aims will
be completed using a large, national sample of commercially insured women aged 20-45 years from 2001-
2019, and will identify women who undergo IVF cycles both with and without insurance coverage and the
infants born from those IVF cycles. The proposed research is innovative because it uses a novel approach to
identify IVF cycles in claims data, including IVF cycles paid for out-of-pocket. In addition, this approach will
allow–for the first time–a robust examination of multiple maternal and infant health outcomes and health care
utilization for one year following IVF and childbirth. The proposed research is significant because it will answer
important questions about the potential benefits to women, infants, and the health care system of insurance
coverage for IVF and will provide evidence to guide major stakeholders. In particular, a better understanding of
the impact of insurance coverage for IVF will lead to healthier women and infants by providing patients,
employers, and policymakers with actionable knowledge that will help them make evidence-based decisions
about insurance coverage for IVF.
项目摘要
关于体外受精保险的存在或不存在如何影响
(IVF)影响妇女和婴儿的健康结果,卫生保健利用率和IVF使用率
富裕的年轻女性研究人员的长期目标是产生令人信服的新证据,
可增进妇女和婴儿的健康。本应用程序的目的是量化的影响,
为不孕妇女及其婴儿提供体外受精保险。核心假设是,
IVF的覆盖率与改善妇女和婴儿的IVF相关健康结果相关;
出生后第一年的医疗保健利用率和总医疗支出;以及增加IVF使用
在不太富裕和年轻的妇女中,通过减轻影响妇女如何使用
试管婴儿该项目的基本原理源于这样一个事实,即很少有健康保险计划涵盖IVF,这导致
两个主要问题。首先,许多女性由于成本而放弃或推迟使用IVF,IVF更成功,
更少的并发症,在年轻的时候进行。第二,当离开支付15,000美元的自掏腰包,
试管婴儿周期,妇女有经济激励,以增加通过转移多个生育的可能性
IVF周期中的胚胎。移植多个胚胎对患者没有额外费用,但
这样做会大大增加双胞胎、三胞胎或其他高风险多胞胎的几率。
对不同不孕症妇女的调查表明,她们愿意在每次试管婴儿中移植较少的胚胎。
如果IVF是由保险覆盖。中心假设将通过追求三个具体目标进行检验:1)
评估IVF保险范围对妇女和婴儿健康结果的影响; 2)
确定IVF保险范围对医疗保健利用的影响; 3)检查
IVF保险覆盖范围对不同收入和年龄组IVF使用的影响。三个目标将
使用2001年以来全国范围内20-45岁商业保险妇女的大样本来完成,
2019年,并将确定接受IVF周期的妇女,无论是否有保险,
这些IVF周期中出生的婴儿。这项研究是创新的,因为它使用了一种新的方法,
在索赔数据中识别IVF周期,包括自付费用的IVF周期。此外,这种方法将
第一次允许对多种母婴健康结果和卫生保健进行强有力的检查
IVF和分娩后使用一年。这项研究很重要,因为它将回答
关于对妇女、婴儿和医疗保险制度的潜在好处的重要问题
覆盖IVF,并将提供证据,以指导主要利益相关者。特别是,更好地了解
保险覆盖IVF的影响将通过为患者提供,
雇主和政策制定者拥有可操作的知识,这将有助于他们做出基于证据的决策
关于试管婴儿的保险
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James M Dupree其他文献
MP76-04 ACCOUNTABLE CARE ORGANIZATIONS AND THE COST AND QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE
- DOI:
10.1016/j.juro.2018.02.2572 - 发表时间:
2018-04-01 - 期刊:
- 影响因子:
- 作者:
Lindsey Herrel;Deborah Kaye;Alice Min;Chad Ellimoottil;James M Dupree;David Miller - 通讯作者:
David Miller
421 AN EARLY LOOK AT SURGICAL PERFORMANCE IN MEDICARE'S HOSPITAL VALUE-BASED PURCHASING PROGRAM: WHO IS WINNING AND WHO IS LOSING
- DOI:
10.1016/j.juro.2013.02.1811 - 发表时间:
2013-04-01 - 期刊:
- 影响因子:
- 作者:
James M Dupree;Jennifer Neimeyer;Megan McHugh - 通讯作者:
Megan McHugh
James M Dupree的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James M Dupree', 18)}}的其他基金
Quantifying the Impact of Insurance Coverage for IVF on Maternal and Infant Health
量化 IVF 保险范围对母婴健康的影响
- 批准号:
10294561 - 财政年份:2021
- 资助金额:
$ 46.06万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 46.06万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 46.06万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 46.06万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 46.06万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 46.06万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 46.06万 - 项目类别: